Literature DB >> 15276315

Implementation of the project 'Support and Consultation on Euthanasia in The Netherlands' (SCEN).

Marijke Catharina Jansen-van der Weide1, Bregje Dorien Onwuteaka-Philipsen, Gerrit van der Wal.   

Abstract

OBJECTIVE: In the project 'Support and Consultation on Euthanasia in The Netherlands' (SCEN), general practitioners (GPs) receive training in formal consultation and in giving expert advice to colleagues who have questions about euthanasia and physician-assisted suicide (EAS). This study describes the way in which this project was implemented in The Netherlands and how it was received by GPs.
METHOD: In the period from April 2000 to December 2002, all GPs in the districts in which SCEN had been implemented received a written post-test questionnaire a year and a half after the start of the project. Registration forms were also filled in by the SCEN physicians and the GPs who contacted SCEN. The post-test questionnaire was returned by 60% of the GPs (n = 3614), and registration forms were returned by 86% (n = 3337) of the GPs who contacted SCEN.
RESULTS: The gradual nation-wide implementation of SCEN was completed within the 4-year study period. Almost all GPs were familiar with the project (99%) and most GPs knew what they could contact SCEN for. Most GPs felt supported by the presence of SCEN, and most GPs also had a positive attitude towards consultation and SCEN. GPs who had received an explicit request for EAS, or had performed EAS, often consulted SCEN physicians (71 and 85%, respectively). Reasons for contacting SCEN were: independence (60%), expertise (58%), and accessibility/availability of a consultant (45%). Reasons for not contacting SCEN were: enough other possibilities for counselling and consultation (48%) only at the beginning of the decision-making process (36%), and sufficient knowledge about EAS (22%). Most GPs intended to use SCEN in the future (96%).
CONCLUSION: The implementation of SCEN has been successful, according to the four steps for successful implementation: awareness, attitude, use and future use. In this respect, linking up with existing networks and good organisation may play an important role. Furthermore, GPs consider it important to have a facility like SCEN which they can contact concerning EAS.

Entities:  

Keywords:  Death and Euthanasia; Empirical Approach

Mesh:

Year:  2004        PMID: 15276315     DOI: 10.1016/j.healthpol.2004.04.010

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  5 in total

Review 1.  Dutch experience of monitoring euthanasia.

Authors:  Bregje D Onwuteaka-Philipsen; Agnes van der Heide; Martien T Muller; Mette Rurup; Judith A C Rietjens; Jean-Jacques Georges; Astrid M Vrakking; Jacqueline M Cuperus-Bosma; Gerrit van der Wal; Paul J van der Maas
Journal:  BMJ       Date:  2005-09-24

2.  Role and involvement of life end information forum physicians in euthanasia and other end-of-life care decisions in Flanders, Belgium.

Authors:  Yanna Van Wesemael; Joachim Cohen; Bregje D Onwuteaka-Philipsen; Johan Bilsen; Wim Distelmans; Luc Deliens
Journal:  Health Serv Res       Date:  2009-09-24       Impact factor: 3.402

3.  Reporting of euthanasia in medical practice in Flanders, Belgium: cross sectional analysis of reported and unreported cases.

Authors:  Tinne Smets; Johan Bilsen; Joachim Cohen; Mette L Rurup; Freddy Mortier; Luc Deliens
Journal:  BMJ       Date:  2010-10-05

4.  Complexities in consultations in case of euthanasia or physician-assisted suicide: a survey among SCEN physicians.

Authors:  Tessa D Bergman; H Roeline W Pasman; Bregje D Onwuteaka-Philipsen
Journal:  BMC Fam Pract       Date:  2020-01-09       Impact factor: 2.497

5.  Establishing specialized health services for professional consultation in euthanasia: experiences in the Netherlands and Belgium.

Authors:  Yanna Van Wesemael; Joachim Cohen; Bregje D Onwuteaka-Philipsen; Johan Bilsen; Luc Deliens
Journal:  BMC Health Serv Res       Date:  2009-12-04       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.